Answers are grounded in this paper and cite their sources.
For decades, intravenous immunoglobulin (IVIg) has provided safe and effective therapy for immunodeficient patients. This proof-of-principle study describes a novel approach to generate personalized IVIg for chronic, antibiotic-resistant infection in real time.
No takes yet. Share an insight, caveat, or question.
Silver et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: